Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

被引:53
|
作者
Chen, Qingyong [1 ]
Fei, Jun [1 ]
Wu, Lijun [1 ]
Jiang, Zhongyong [1 ]
Wu, Yuquan [1 ]
Zheng, Yun [1 ]
Lu, Guohua [2 ]
机构
[1] 117th Hosp PLA, Dept Resp Dis, Hangzhou 310013, Zhejiang, Peoples R China
[2] Zhejiang Univ, Dept Resp Dis, Affiliated Hosp 1, Coll Med, Hangzhou 310004, Zhejiang, Peoples R China
关键词
cathepsin B; cathepsin L; cysteine C; urokinase plasminogen activator; urokinase plasminogen activator receptor; lung cancer; progonosis; sera; INHIBITORS STEFIN-A; PROGNOSTIC-SIGNIFICANCE; PULMONARY ADENOCARCINOMAS; CLINICAL-SIGNIFICANCE; CYSTEINE PROTEINASES; COLORECTAL-CANCER; EXPRESSION; METASTASIS; PROTEASES; PROGRESSION;
D O I
10.3892/ol.2011.302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to determine the levels of cathepsin B (cath B), cathepsin L (cath L), cystatin C, urokinase plasminogen activator (u-PA) and urokinase plasminogen activator receptor (u-PAR) in the sera of patients with lung cancer compared to healthy controls using ELISA. Concomitantly, the relationship between the components and clinicopathological prognosis was analyzed. The study included 30 healthy volunteers and 105 lung cancer patients. Blood samples were collected and cath B, cath L, cystatin C, u-PA and u-PAR measurements were made using ELISA. Results showed that the levels of cath B, cath L, cystatin C, u-PA and u-PAR were significantly higher in the patient group compared to the healthy controls. The significance was marked for cath B and mild for u-PAR in correlation with lymph node metastasis. There was no significance for other parameters. Notably, patients with a combination of high cystatin C and high cath B levels had significantly lower survival probability as compared to those with cystatin C(+)/cath B(-) or with cystatin C(-)/cath B(-), Similarly, patients with a combination of high u-PA and u-PAR experienced significantly shorter survival., Furthermore, the univariate analysis revealed that cath B, u-PAR, lymph node metastases, stage and grade were related to survival. However, findings of the multivariate Cox analysis indicated that the sera levels of cath B, u-PAR and lymph node metastases may serve as independent prognostic variables in patients with lung cancer.
引用
收藏
页码:693 / 699
页数:7
相关论文
共 50 条
  • [1] Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells
    Hjertner, Ö
    Qvigstad, G
    Hjorth-Hansen, H
    Seidel, C
    Woodliff, J
    Epstein, J
    Waage, A
    Sundan, A
    Börset, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (04) : 815 - 822
  • [2] UROKINASE PLASMINOGEN-ACTIVATOR AND UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR IN BREAST-CANCER
    DUGGAN, C
    MAGUIRE, T
    MCDERMOTT, E
    OHIGGINS, N
    FENNELLY, JJ
    DUFFY, MJ
    INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (05) : 597 - 600
  • [3] Urokinase plasminogen activator and cathepsin D in micrometastatic cells of patients with primary breast cancer
    Solomayer, EF
    Diel, IJ
    Gollan, C
    Meyberg, G
    Bode, S
    Wallwiener, D
    Bastert, G
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S23 - S24
  • [4] Immunohistochemical Detection of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor in Canine Vascular Endothelial Tumours
    Anwar, Sh.
    Yanai, T.
    Sakai, H.
    JOURNAL OF COMPARATIVE PATHOLOGY, 2015, 153 (04) : 278 - 282
  • [5] Urokinase plasminogen activator receptor in breast cancer
    Brunner, N
    HolstHansen, C
    Pedersen, AN
    Pyke, C
    HoyerHansen, G
    Foekens, J
    Stephens, RW
    BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, 1996, : 201 - 207
  • [6] THE RECEPTOR FOR UROKINASE-PLASMINOGEN ACTIVATOR
    BLASI, F
    STOPPELLI, MP
    CUBELLIS, MV
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, 32 (03) : 179 - 186
  • [7] THE RECEPTOR FOR THE UROKINASE PLASMINOGEN-ACTIVATOR
    BLASI, F
    STOPPELLI, P
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, : 236 - 236
  • [8] Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma
    Häckel, CG
    Krueger, S
    Grote, HJ
    Oshiro, Y
    Hodges, S
    Johnston, DA
    Johnson, ME
    Roessner, A
    Ayala, AG
    Czerniak, B
    CANCER, 2000, 89 (05) : 995 - 1003
  • [9] Identification of urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) as therapeutic targets for pancreatic cancer.
    Della Croce, K
    Han, H
    Beroza, P
    Bearss, DJ
    von Hoff, DD
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3668S - 3668S
  • [10] Urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) serum level in patients with malignant lymphomas
    Hus, I
    Cioch, M
    Jawniak, D
    Manko, J
    Dmoszynska, A
    Chrapko, M
    Hus, M
    BULLETIN OF THE VETERINARY INSTITUTE IN PULAWY, 2002, : 141 - 144